MYDX - MyDx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.005
-0.001 (-11.567%)
At close: 3:50PM EST
Stock chart is not supported by your current browser
Previous Close0.006
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume13,743,486
Market Cap9.316M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.013
Earnings DateNov 24, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    CNW Grouplast month

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswirelast month

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    Partnering with the Leading Israeli Research and Development Organizations and Hospitals Devoted to the Scientific Study of Cannabis SAN DIEGO , Jan. 16, 2018 /PRNewswire/ --  MyDx, Inc.  (OTCQB: MYDX), ...

  • MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula
    PR Newswirelast month

    MyDx's Biopharmaceutical Division Commences Clinical Trials On Its Unique MyDx360 Pain Management Formula

    SAN DIEGO, Jan. 16, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced a definitive agreement and statement of work with a contract research organization to commence clinical trials in Israel on its proprietary pain management formula that was derived from 50,000+ pre-clinical, crowd-sourced physiological data-points tracked by MyDx's Handheld Cannabis Tester and associated mobile app.

  • PR Newswirelast month

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    SAN DIEGO, Jan. 11, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has recruited Dr. Jessica Peatross (Dr. Jess) as its Chief Medical Officer. Dr. Jess will lead the Clinical Research Initiatives that MyDx expects to begin soon as well as support formulation services offered to MyDx360 Customers. Dr. Jessica Peatross is a western trained, board certified medical doctor and Gerson Therapy practitioner who began her journey into healing in 2009 when she graduated from the University of Louisville (KY) Internal Medicine residency program.

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    PR Newswirelast month

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    Board Certified Internal Medicine Doctor to Lead MyDx Clinical Research Initiatives and Support MyDx360 Formulations Services SAN DIEGO , Jan. 11, 2018 /PRNewswire/ --  MyDx, Inc. (OTC: MYDX), a science ...

  • MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer
    CNW Grouplast month

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

    MyDx Appoints Dr. Jessica Peatross As Chief Medical Officer

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire2 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    CNW Group2 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

  • MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects
    PR Newswire2 months ago

    MyDx Forms Exclusive Partnership With Highsmen Genetics To Offer Custom Cannabis Strains Tailored For Desired Physiological Effects

    SAN DIEGO, Jan. 4, 2018 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming.

  • MyDx Cancels Reverse Stock Split
    CNW Group2 months ago

    MyDx Cancels Reverse Stock Split

    MyDx Cancels Reverse Stock Split

  • MyDx Cancels Reverse Stock Split
    PR Newswire2 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPen™, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Cancels Reverse Stock Split
    PR Newswire2 months ago

    MyDx Cancels Reverse Stock Split

    SAN DIEGO, Dec. 20, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced that based upon recent and anticipated developments for the Company, the board has decided to cancel its plans for the reverse stock split approved earlier this year. "With the influx of interest for our MyDx360 services, including ancillary products such as the EcoSmartPenTM, as well as the progress we have made in the analysis of our 55K+ data points and the development of MyDx crowdsourced formulations, we are very optimistic about where the Company is headed into 2018.

  • MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen
    PR Newswire2 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDxTM Handheld Tester and its ECOSmartPenTM in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.

  • CNW Group2 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

  • PR Newswire2 months ago

    MyDx Seeks Medical Device Designation For CannaDx And The ECOSmartPen

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it submitted an application and is seeking medical device designation in Canada for its CannaDx™ Handheld Tester and its ECOSmartPen™ in order to make its products more accessible to medicinal users seeking to track and manage their consumption habits and prevent abuse.

  • MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen(TM)
    PR Newswire3 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen(TM)

    SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device -- The ECOSmartPenTM -- and is now accepting Pre-Orders. The ECO Smart PenTM by MyDx is a next generation, rechargeable delivery pen with Bluetooth technology capable of monitoring dosages and consumer feedback. The ECO Smart Pen also comes equipped with remote access and child safety protection via the EcoSmartPen App and is designed to help patients and consumers better manage and regulate their cannabis consumption habits, while protecting their children from unsupervised use.

  • PR Newswire3 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen™

    SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced it filed patents on its revolutionary, second smart device – The ECOSmartPenTM – and is now accepting Pre-Orders. The ECO Smart PenTM by MyDx is a next generation, rechargeable delivery pen with Bluetooth technology capable of monitoring dosages and consumer feedback. The ECO Smart Pen also comes equipped with remote access and child safety protection via the EcoSmartPen App and is designed to help patients and consumers better manage and regulate their cannabis consumption habits, while protecting their children from unsupervised use.

  • CNW Group3 months ago

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen™

    MyDx Files Patents & Is Now Accepting Preorders For The ECOSmartPen™

  • MyDx Provides Corporate Update & Launches New Website
    PR Newswire4 months ago

    MyDx Provides Corporate Update & Launches New Website

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced the launch of its new website, www.mydxlife.com, a reimagining of its brand with greater clarification of its products and services. The structure of the new site aligns with MyDx's re-organized business segments and is set up for new customers to explore and purchase products from each of those new segments, seamlessly.

  • PR Newswire4 months ago

    MyDx Provides Corporate Update & Launches New Website

    SAN DIEGO, Oct. 11, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments it alleviates, today announced the launch of its new website, www.mydxlife.com, a reimagining of its brand with greater clarification of its products and services. The structure of the new site aligns with MyDx's re-organized business segments and is set up for new customers to explore and purchase products from each of those new segments, seamlessly.

  • MyDx Featured by Canadian Tier 1 Business News Network (BNN), Toronto Life Magazine, and Global News
    PR Newswire6 months ago

    MyDx Featured by Canadian Tier 1 Business News Network (BNN), Toronto Life Magazine, and Global News

    SAN DIEGO, Aug. 29, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a rapidly growing science and technology company that has developed MyDx®, the first multi-use handheld chemical analyzer for consumers, announced that it was recently featured by Canadian Tier 1 Media Outlets including Business News Network (BNN), Toronto Life Magazine, and Global News. CEO Daniel Yazbeck will also be speaking on a panel at MJAC2017 InvestorsHub International Cannabis Conference entitled "Investing in the Picks and Shovels of the Industry" at 12:00 p.m. Pacific Time on Saturday September 2nd at the JW Marriott Los Angeles.

  • PR Newswire6 months ago

    MyDx Featured by Canadian Tier 1 Business News Network (BNN), Toronto Life Magazine, and Global News

    CEO Daniel Yazbeck to Speak at InvestorsHub International Cannabis Conference in Los Angeles this weekend SAN DIEGO , Aug. 29, 2017 /PRNewswire/ --  MyDx, Inc.  (OTCQB: MYDX), a rapidly growing science ...

  • PR Newswire6 months ago

    MyDx Reports Second Quarter Results

    MyDx sold out of its signature handheld analyzer in Q1 on stronger than expected demand leading to a backlog of orders and customer deposits that are were filled in Q2. The Company expects to continue to receive consistent growing demand for its analyzer based on word of mouth and referrals mainly as well as a new marketing initiatives the company launched late June which is generating new customer awareness and product orders from Canada.

  • MyDx Reports Second Quarter Results
    PR Newswire6 months ago

    MyDx Reports Second Quarter Results

    MyDx sold out of its signature handheld analyzer in Q1 on stronger than expected demand leading to a backlog of orders and customer deposits that are were filled in Q2. The Company expects to continue to receive consistent growing demand for its analyzer based on word of mouth and referrals mainly as well as a new marketing initiatives the company launched late June which is generating new customer awareness and product orders from Canada.

  • PR Newswire7 months ago

    MyDx Files Complaint Against Former Chief Operating Officer, Protects Unique AeroDx Diagnostic Platform and Addresses Toxic Financier's Unauthorized Conversion

    SAN DIEGO, July 18, 2017 /PRNewswire/ -- MyDx, Inc. (MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer initially designed for cannabis professionals and retail consumers to measure the chemicals in cannabis and track their feedback on how each sample is impacting their physiology, today announced that all previously reported variable toxic debts have been satisfied through the unauthorized conversion of the Crown Bridge note and has also filed a lawsuit against its former COO and other defendants who have attempted to create a competitive advantage with its anticipated product launch of its air quality sensor: AeroDx®. On July 14, 2017, the Company and its Chief Executive Officer, Daniel Yazbeck, filed a complaint in Superior Court of California against a series of Defendants who have allegedly engaged in unfair business practices, made false statements about the Company, its products, and Mr. Yazbeck at investor events and on online investor platforms.  There can be no assurance about the results or on the outcome of the lawsuit, however, the company took aggressive steps it felt were necessary to protect its business and its shareholders.